1. Medtech Insight
  2. >>Business
  3. >>Deals

Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

 
• By Natasha Barrow

Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

• Source: Shutterstock

"Unicorn" start-up Owkin and AstraZeneca are developing an AI-powered breast cancer prescreening solution under a partnership announced on 2 October.

According to French-American Owkin, which bills itself as “the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics,” the AI tool in development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business